Randomized Trialhigh evidence
Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.
JAMA·January 6, 2026·PMID 41324946
Why it mattersLevosimendan is sometimes used off-label to aid ECMO weaning, but robust evidence has been lacking. This trial provides high-quality data that early routine use does not improve weaning success or survival and may increase arrhythmic risk.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled